Logo
x

Search

Subscribe Now

Axsome Therapeutics

Axsome Therapeutics Receives the US FDA Approval for Symbravo (meloxicam and rizatriptan) to Treat Migraine

Axsome Therapeutics Receives the US FDA Approval for Symbravo (meloxicam and rizatriptan) to Treat Migraine

  • January 31, 2025
Axsome Therapeutics Reports Data from P-III (ACCORD-2 & ADVANCE-2) Trials of AXS-05 in Alzheimer’s Disease Agitation

Axsome Therapeutics Reports Data from P-III (ACCORD-2 & ADVANCE-2) Trials of AXS-05 in Alzheimer’s Disease Agitation

  • December 31, 2024
PharmaShots Weekly Snapshots (March 26 – March 29, 2024)

PharmaShots Weekly Snapshots (March 26 – March 29, 2024)

  • March 29, 2024
Axsome Therapeutics Reports Results for AXS-12 in P-III Trial for the Treatment of Narcolepsy

Axsome Therapeutics Reports Results for AXS-12 in P-III Trial for the Treatment of Narcolepsy

  • March 26, 2024
Axsome Therapeutics Reports the First Patient Dosing of Solriamfetol in the P-III Trial (FOCUS) for Adults with Attention Deficit Hyperactivity Disorder

Axsome Therapeutics Reports the First Patient Dosing of Solriamfetol in the P-III Trial (FOCUS) for Adults with Attention Deficit...

  • July 10, 2023
Axsome Therapeutics Entered into an Exclusive License Agreement with Pharmanovia to Develop and Commercialize Sunosi (solriamfetol) in Europe

Axsome Therapeutics Entered into an Exclusive License Agreement with Pharmanovia to Develop and Commercialize Sunosi (solriamfetol...

  • February 23, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.